Nanologica offers a range of high-class chromatography resins. Due to excellent separation qualities and long lifetimes for the products,
they can streamline purification workflows and lower manufacturing costs for pharmaceutical manufacturers.
NLAB Saga® is a perfectly spherical, fully porous silica with superior mechanical stability and exceptional
chemical stability at high and low pH, making it an optimum choice for large scale purification of peptides.
Read more in our catalogue:
Interview with Katarina Alenäs,
SVP Chromatography
Interview with Olga Krivosheeva, Ph.D.
Application Project Manager
Interview with Chunfang Zhou, Ph.D.
Sales Manager China
NLAB Saga® is sold in bulk. Please contact sales@nanologica.com for more information and orders.
Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances.
Nanologica develops, manufactures, and sells advanced chromatography media to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity.
The Group also includes Syntagon, a contract manufacturer of drug molecules for both clinical studies and commercial delivery. Syntagon works with chemical engineering manufacturing and the development of processes and analyses of pharmaceutical raw materials, with a core competence in small molecules and peptides, and a particular strength in purification and analysis of complex compounds.
Nanologica is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.
Nanologica’s Chief Financial Officer Eva Osterman has decided to leave the company. Eva will remain in the Group until 31 August 2026 to ensure a smooth handover and support the recruitment of her successor. The recruitment process has begun. “Since she started in 2017, Eva has had a central role
Vd Andreas Bhagwani intervjuas om Nanologicas Q1-rapport. Intervjun gjordes 22 maj 2026. Rapporten i sin helhet finns här: Svenska Engelska
Nanologica AB (publ) today May 21, 2026 held its Annual General Meeting in Stockholm, at which the following resolutions were adopted. Adoption of the income statement and balance sheet, disposition of result The Annual General Meeting adopted the income statement and balance sheet for the company and the group
CEO Andreas Bhagwani presentas the company. Videos in English and in Swedish.
Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market under the ticker NICA. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.
